Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 27, 2026, 15:00 JST
CellSource Co.,Ltd. [4880.NG]
TOKYO, Feb 27 (Pulse News Wire) – CellSource Co.,Ltd. (4880.T) released its earnings presentation for Q3 FY2026.
Revenue was ¥83 million (+14.0% YoY). Operating profit was ¥16 million. Ordinary profit was ¥17 million.
Total assets stood at ¥14.8 trillion. For the full year, the company forecasts revenue of ¥83 million. Forecast operating profit is ¥16 million.
AI-translated content. 🟢 Confidence:
TOKYO, Feb 27 (Pulse News Wire) – CellSource Co.,Ltd. (4880.T) released its earnings presentation for Q3 FY2026.
0% YoY).
8 trillion.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
